Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862658 | 0.90 | KEAP1 (0.51) | MCL1KEAP1NFE2L2BCL2L1 | |
| SCHEMBL6864347 | 0.86 | MRGPRX4 (0.52) | KEAP1NFE2L2MRGPRX4PTGER1CXCR3 | |
| SCHEMBL6856074 | 0.86 | KEAP1 (0.47) | MCL1KEAP1NFE2L2MRGPRX4BCL2L1 | |
| SCHEMBL27492548 | 0.85 | PSEN1 (0.45) | KEAP1NFE2L2MRGPRX4PTGER1PSEN1 | |
| SCHEMBL27490796 | 0.85 | PSEN1 (0.47) | KEAP1NFE2L2PTGER1PSEN1PSEN2 | |
| SCHEMBL6855425 | 0.82 | POLB (0.54) | KEAP1NFE2L2MRGPRX4PTGER1PSEN1 | |
| SCHEMBL6860607 | 0.82 | MAPT (0.47) | KEAP1NFE2L2MRGPRX4PSEN1PSEN2 | |
| SCHEMBL6861447 | 0.82 | KEAP1 (0.47) | KEAP1NFE2L2 | |
| SCHEMBL6861217 | 0.80 | AKR1C3 (0.49) | KEAP1NFE2L2PSEN1PSEN2APH1B | |
| SCHEMBL6861220 | 0.80 | AKR1C3 (0.49) | KEAP1NFE2L2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | claimed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | claimed |
| CN-1247529-A | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2000-03-15 | — | — | CN | claimed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | claimed |
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| US-6790866-B2 | SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6448290-B1 | PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| CN-1247529-A | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2000-03-15 | — | — | CN | disclosed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | CNR1, HCAR1, HCAR2 | MCL1 3321/4885KEAP1 2167/4885NFE2L2 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.